WuXi AppTec Co Ltd
SSE:603259
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
WuXi AppTec Co Ltd
EPS (Diluted)
WuXi AppTec Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
WuXi AppTec Co Ltd
SSE:603259
|
EPS (Diluted)
¥6
|
CAGR 3-Years
33%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
EPS (Diluted)
¥0
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
EPS (Diluted)
¥1
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
EPS (Diluted)
¥1
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
16%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
EPS (Diluted)
¥1
|
CAGR 3-Years
105%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
Glance View
In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.
See Also
What is WuXi AppTec Co Ltd's EPS (Diluted)?
EPS (Diluted)
6.6
CNY
Based on the financial report for Dec 31, 2025, WuXi AppTec Co Ltd's EPS (Diluted) amounts to 6.6 CNY.
What is WuXi AppTec Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
45%
Over the last year, the EPS (Diluted) growth was 102%. The average annual EPS (Diluted) growth rates for WuXi AppTec Co Ltd have been 33% over the past three years , 45% over the past five years .